Zeneca launches cancer diagnostic kit:
This article was originally published in Clinica
Uk-based Zeneca Diagnostics has launched its first cancer diagnostic kit, Elucigene K-RAS7, in Europe. The test detects the seven most common mutations in the K-ras proto-oncogene, found in the DNA of many types of cancer cells - including bowel, pancreatic and lung cancer. Zeneca claims the test is sufficiently sensitive to spot K-ras mutations even in samples containing predominantly normal tissue. It can thus give early warning of malignancy as well as typing and monitoring of known tumours. The kit is the fourth in the Elucigene series.
You may also be interested in...
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.
The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.
Amid several new and updated draft guidance documents and the potential approach of the first approval, interchangeability continues to be a buzzword in US biosimilars. AbbVie has projected that two Humira (adalimumab) biosimilars will hold the designation when they launch in 2023.